Harrow Health, Inc. (HROW)

NASDAQ: HROW · IEX Real-Time Price · USD
25.01
+0.42 (1.71%)
At close: Jul 19, 2024, 4:00 PM
25.09
+0.08 (0.32%)
After-hours: Jul 19, 2024, 7:38 PM EDT
1.71%
Market Cap 884.90M
Revenue (ttm) 138.68M
Net Income (ttm) -31.33M
Shares Out 35.38M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 316,725
Open 24.75
Previous Close 24.59
Day's Range 24.40 - 25.48
52-Week Range 7.60 - 25.58
Beta 0.77
Analysts Strong Buy
Price Target 28.00 (+11.96%)
Earnings Date Aug 7, 2024

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e... [Read more]

Sector Healthcare
Founded 1998
Employees 315
Stock Exchange NASDAQ
Ticker Symbol HROW
Full Company Profile

Financial Performance

In 2023, Harrow Health's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 11.96% from the latest price.

Price Target
$28.0
(11.96% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Harrow to Attend 2024 ASRS Annual Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Soc...

8 days ago - Business Wire

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement w...

11 days ago - Business Wire

Top 3 Health Care Stocks That May Crash This Quarter

As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Other symbols: LBPHLLY
17 days ago - Benzinga

Harrow Provides TRIESENCE® Relaunch Update

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three com...

4 weeks ago - Business Wire

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first pati...

6 weeks ago - Business Wire

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE...

6 weeks ago - Business Wire

Harrow to Present at Two Investor Conferences in May

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves...

2 months ago - Business Wire

Harrow Announces First Quarter 2024 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company a...

2 months ago - Business Wire

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, H...

2 months ago - Business Wire

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ende...

3 months ago - Business Wire

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of i...

3 months ago - Business Wire

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Compan...

4 months ago - Business Wire

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth q...

4 months ago - Business Wire

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

NASHVILLE, Tenn. & TORONTO--(BUSINESS WIRE)---- $HROW--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada's largest pharmaceutical company, ...

5 months ago - Business Wire

Harrow Announces New Appointments to its Board of Directors

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to ...

6 months ago - Business Wire

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑...

6 months ago - Business Wire

Harrow Partners with Leading Healthcare Market Access Technology Platforms

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platfo...

7 months ago - Business Wire

Harrow Completes Transfer of the TRIESENCE® New Drug Application

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application ...

8 months ago - Business Wire

Harrow to Present at Two Investor Conferences in November

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Fi...

8 months ago - Business Wire

Harrow Announces Third Quarter 2023 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023. The...

8 months ago - Business Wire

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ende...

9 months ago - Business Wire

Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications...

9 months ago - Business Wire

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health...

10 months ago - Business Wire

Harrow Announces Second Quarter 2023 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second quarter and six months ended June 30, 2023. Th...

1 year ago - Business Wire

Harrow Launches VIGAMOX® in the U.S.

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application ...

1 year ago - Business Wire